![Ann Hanham](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ann Hanham
Direktor/Vorstandsmitglied bei
SCYNEXIS, INC.
Vermögen: 10 240 $ am 31.05.2026
Profil
Ann F.
Hanham was the founder of InterMune, Inc. (1998) as Vice President-Clinical & Regulatory Affairs.
Dr. Hanham is the founder of BAR Capital Management LLC (2013) as Managing Director & Founding Partner.
Dr. Hanham is the founder of Bar Capital LLC (2013) as Managing Partner.
Dr. Hanham is currently an Independent Director at SCYNEXIS, Inc. since 2008.
Former positions include Chairman at Adlyfe, Inc., Medical Director at Celtrix Pharmaceuticals, Inc. (1991-1995), Director at Acusphere, Inc., Director at Immunicon Corp., Director at Sention, Inc., Director at Aerovance, Inc., Director at BioMimetic Therapeutics, Inc. (2006), Director at Waterstone Pharmaceuticals, Inc., Managing Director & General Partner at Burrill LLC (2000-2013), Director at Biotie Therapies Oy (2010), Director at Targacept, Inc. (2006), Director at Veritas Medicine, Inc., Independent Director at Endocyte, Inc. (2011-2018), Senior Director-Oncology Product Development at Otsuka America Pharmaceutical, Inc. (1995-1998), Director at Logical Therapeutics, Inc., Director at NewBridge Pharmaceuticals FZ LLC, Director at Taiwan Liposome Co., Ltd., Lead Independent Director at HTG Molecular Diagnostics, Inc. (2019-2021), and Senior Manager-Medical Affairs at Becton, Dickinson & Co. (1984-1991).
Education includes a doctorate from the University of British Columbia, a graduate degree from Simon Fraser University, and an undergraduate degree from the University of Toronto.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SCYNEXIS, INC. 0.02% | 01.04.2026 | 14’525 ( 0.02% ) | 10 240 $ | 31.05.2026 |
Aktive Positionen von Ann Hanham
| Unternehmen | Position | Beginn |
|---|---|---|
| SCYNEXIS, INC. | Direktor/Vorstandsmitglied | 01.12.2008 |
Ehemalige bekannte Positionen von Ann Hanham
| Unternehmen | Position | Ende |
|---|---|---|
| ENDOCYTE, INC. | Direktor/Vorstandsmitglied | 01.01.2018 |
Bar Capital LLC | Corporate Officer/Principal | 01.03.2017 |
BAR Capital Management LLC
 BAR Capital Management LLC Investment ManagersFinance BAR Capital Management LLC invests in companies located globally. The firm focuses on companies operating in the fields of biotechnology, pharmaceuticals, diagnostics, medical devices, human healthcare & related medical technologies, wellness & nutraceuticals, agbio and industrial biotechnology (biomaterials/bioprocess). It provides financing for seed, early stage and mezzanine capital requirements with an investment size ranging between $1 and $20 million per company. | Corporate Officer/Principal | 31.12.2016 |
Burrill LLC
 Burrill LLC Investment ManagersFinance Burrill invests in companies located in the United States. The firm focuses on a broad range of sectors. It participates in buyout and early-stage transactions. | Vorstandsvorsitzender | 01.11.2013 |
Veritas Medicine, Inc.
 Veritas Medicine, Inc. Internet Software/ServicesTechnology Services Operates an online database of clinical trials | Direktor/Vorstandsmitglied | 16.05.2011 |
Ausbildung von Ann Hanham
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
67
Beziehungen ersten Grades
26
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 26 |
|---|---|
Becton, Dickinson & Co.
 Becton, Dickinson & Co. Medical SpecialtiesHealth Technology Manufactures and sells medical supplies, devices, laboratory equipment & diagnostic products | Health Technology |
Celtrix Pharmaceuticals, Inc.
 Celtrix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops potential therapeutic products | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that researches and develops therapies in pulmonology & orphan fibrotic diseases | Health Technology |
Acusphere, Inc.
 Acusphere, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes drugs | Health Technology |
Immunicon Corp.
 Immunicon Corp. Medical SpecialtiesHealth Technology Develops cell-based research and diagnostic products | Health Technology |
Sention, Inc.
 Sention, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Health Technology |
Aerovance, Inc.
 Aerovance, Inc. Medical DistributorsDistribution Services Develops drugs for respiratory and inflammatory diseases | Distribution Services |
HTG Molecular Diagnostics, Inc.
 HTG Molecular Diagnostics, Inc. Miscellaneous Commercial ServicesCommercial Services Provides molecular technology solutions | Commercial Services |
BioMimetic Therapeutics, Inc.
 BioMimetic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and sells protein therapeutics for tissue and organ regeneration | Health Technology |
Adlyfe, Inc.
 Adlyfe, Inc. Medical DistributorsDistribution Services Develops diagnostic products | Distribution Services |
Waterstone Pharmaceuticals, Inc.
 Waterstone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in activities ranging from drug discovery of proprietary new chemical entities, custom development and manufacturing services, and generic drug development and manufacturing | Health Technology |
Burrill LLC
Burrill LLC Investment ManagersFinance Burrill invests in companies located in the United States. The firm focuses on a broad range of sectors. It participates in buyout and early-stage transactions. | Finance |
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
SCYNEXIS, Inc.
 SCYNEXIS, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections | Health Technology |
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Discovers and develops nicotinic acetylcholine receptor based therapies | Health Technology |
University of British Columbia
 University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Simon Fraser University
 Simon Fraser University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Toronto
 University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Veritas Medicine, Inc.
Veritas Medicine, Inc. Internet Software/ServicesTechnology Services Operates an online database of clinical trials | Technology Services |
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for cancer and inflammatory diseases | Health Technology |
Otsuka America Pharmaceutical, Inc.
 Otsuka America Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceutical products | Health Technology |
Logical Therapeutics, Inc.
 Logical Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops products that treat diseases associated with inflammation | Health Technology |
NewBridge Pharmaceuticals FZ LLC
 NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceuticals, therapeutics, and medical devices | Health Technology |
Taiwan Liposome Co., Ltd.
 Taiwan Liposome Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company | Health Technology |
BAR Capital Management LLC
BAR Capital Management LLC Investment ManagersFinance BAR Capital Management LLC invests in companies located globally. The firm focuses on companies operating in the fields of biotechnology, pharmaceuticals, diagnostics, medical devices, human healthcare & related medical technologies, wellness & nutraceuticals, agbio and industrial biotechnology (biomaterials/bioprocess). It provides financing for seed, early stage and mezzanine capital requirements with an investment size ranging between $1 and $20 million per company. | Finance |
Bar Capital LLC |
